0001104659-16-110481.txt : 20160408 0001104659-16-110481.hdr.sgml : 20160408 20160408080810 ACCESSION NUMBER: 0001104659-16-110481 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160408 FILED AS OF DATE: 20160408 DATE AS OF CHANGE: 20160408 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Nabriva Therapeutics AG CENTRAL INDEX KEY: 0001641640 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: C4 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37558 FILM NUMBER: 161561340 BUSINESS ADDRESS: STREET 1: LEBERSTRASSE 20 CITY: VIENNA STATE: C4 ZIP: 1110 BUSINESS PHONE: 43 (0)1 740 93-0 MAIL ADDRESS: STREET 1: LEBERSTRASSE 20 CITY: VIENNA STATE: C4 ZIP: 1110 6-K 1 a16-8156_16k.htm 6-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of April 2016

 

Commission File Number 001-37558

 

 

NABRIVA THERAPEUTICS AG

(Translation of registrant’s name into English)

 

 

Leberstrasse 20

1110 Vienna, Austria; Tel: +43 (0)1 740 930

(Address of principal executive office)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

FORM 20-F  x

 

FORM 40-F  o

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  o

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  o

 

 

 


 

Departure of Officer

 

On April 7, 2016, Ralf Schmid provided notice of his resignation as chief financial officer and chief operating officer of Nabriva Therapeutics AG (the “Company”) in order to pursue other interests. Mr. Schmid’s resignation will become effective May 31, 2016 (the “Separation Date”). From the Separation Date through August 31, 2016, Mr. Schmid has agreed to provide consulting services to the Company on an as requested basis. The Company expects to enter into a consulting agreement with Mr. Schmid on or before the Separation Date to formally document this arrangement.

 

The Company has commenced a search for a new chief financial officer to be based in the Company’s King of Prussia, Pennsylvania office.

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

 

 

 

 

NABRIVA THERAPEUTICS AG

 

 

 

 

By:

/s/ Colin Broom

 

 

Colin Broom

 

 

Chief Executive Officer

 

Date: April 8, 2016

 

2